Hangzhou Just Biotherapeutics Co Ltd (Just China), an affiliate of Seattle-based Just Biotherapeutics, has closed a RMB400 million ($59 million) Series B round led by Singapore state investment firm Temasek Holdings, the China Money Network reported.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com